Liptruzet Approved By FDA To Cut Cholesterol, Despite Criticism By Cardiologists

Liptruzet, a cholesterol-lowering drug that combines Merck’s Zetia (ezetimibe) with atorvastatin (generic version of Pfizer’s Lipitor) has been approved by the US FDA (Food and Drug Administration). According to Merck and Co, Liptruzet tablets are for the treatment of high LDL (low-density lipoprotein) cholesterol in patients with primary or mixed hyperlipidemia alongside a special diet when diet alone is not enough. Hyperlipidemia is an excessively high concentration of fats (lipids) in the blood. LDL is also known as “bad cholesterol”, as opposed to HDL (the good one – high-density lipoprotein). According to Merck, Liptruzet contains ezetimibe, an effective drug for…
View More/Source Article